Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study

Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study

Background Dupilumab is a monoclonal antibody against the IL-4/IL-13 receptor-subunit approved for the treatment of moderate-severe atopic dermatitis (AD). Some attempts to increase dose interval have been described in both trial and real-world settings. Objective This study aimed to identify predic...

Full description

Bibliographic Details
Main Authors: Andrea Chiricozzi, Giacomo Dal Bello, Niccolò Gori, Lucia Di Nardo, Donatella Schena, Giacomo Caldarola, Martina Maurelli, Clara De Simone, Giampiero Girolomoni, Ketty Peris
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Dermatological Treatment
Subjects:
atopic dermatitis
atopic eczema
dose spacing
dupilumab
predictive factors
Online Access:http://dx.doi.org/10.1080/09546634.2023.2235041

Internet

http://dx.doi.org/10.1080/09546634.2023.2235041

Similar Items